Compare UIS & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UIS | MDWD |
|---|---|---|
| Founded | 1942 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.7M | 193.3M |
| IPO Year | 1994 | 2013 |
| Metric | UIS | MDWD |
|---|---|---|
| Price | $2.08 | $16.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.67 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 536.2K | 89.7K |
| Earning Date | 04-29-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,950,100,000.00 | N/A |
| Revenue This Year | N/A | $48.88 |
| Revenue Next Year | $2.60 | $35.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.00 | $14.90 |
| 52 Week High | $5.33 | $22.51 |
| Indicator | UIS | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 51.54 |
| Support Level | N/A | $16.77 |
| Resistance Level | $2.65 | $18.71 |
| Average True Range (ATR) | 0.08 | 0.85 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 25.40 | 71.68 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.